美巴那肼
 | |
| 臨床資料 | |
|---|---|
| 给药途径 | 口服 |
| ATC碼 |
|
| 法律規範狀態 | |
| 法律規範 |
|
| 识别信息 | |
| |
| CAS号 | 65-64-5 |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.559 |
| 化学信息 | |
| 化学式 | C8H12N2 |
| 摩尔质量 | 136.20 g·mol−1 |
美巴那肼（商品名Actomol）是一种单胺氧化酶抑制剂，化学式为C8H12N2。它于1960年代曾用作抗抑郁药，但现因其肝毒性而被撤回。[1][2][3]动物实验发现美巴那肼是比苯异丙肼更强的单胺氧化酶抑制剂，治疗指数更大。[4]
参考资料
[编辑]- ^ Gilmour SJ. Clinical trial of mebanazine--a new monoamine oxidase inhibitor. The British Journal of Psychiatry. September 1965, 111 (478): 899–902. PMID 5889715. S2CID 46651861. doi:10.1192/bjp.111.478.899.
- ^ Barker JC, Jan IA, Enoch MD. A controlled trial of mebanazine ('Actomol') in depression. The British Journal of Psychiatry. November 1965, 111 (480): 1095–100. PMID 5320546. S2CID 6803488. doi:10.1192/bjp.111.480.1095.
- ^ Knott F. A preliminary trial of mebanazine in depressive states. The Journal of New Drugs. 1965, 5 (6): 345–7 [2024-02-11]. PMID 5327282. doi:10.1002/j.1552-4604.1965.tb00259.x. （原始内容存档于2023-02-18）.
- ^ Biel, J. H. Annual Reports in Medicinal Chemistry. Chapter 2. Antidepressants, Stimulants, Hallucinogens. Annual Reports in Medicinal Chemistry 2. Elsevier. 1967: 11–23 [2024-02-11]. ISBN 9780120405022. doi:10.1016/S0065-7743(08)61499-2. （原始内容存档于2018-07-01）.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
